Pfizer Stock Rises Slightly Ahead of Q3 Earnings, But Full Year Declines Expected

Pfizer (PFE) stock rose 0.21% but lagged the broader market gains.

The company is set to report earnings on October 31, with estimates calling for a 66.85% EPS decline.

Revenue is expected to fall 35.87% compared to last year's quarter.

For the full year, analysts forecast a 49.39% EPS decline and a 33.9% revenue drop.

Recent positive estimate revisions reflect near-term business momentum. The Zacks Rank system can help capitalize on this.

Pfizer currently holds a Zacks Rank #3 (Hold) and trades at an attractive valuation.